AK Medical Holdings Limited (Stock Code: 1789), the bestselling brand of orthopedic joint implants in China, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong at 9:30am today, under the stock code 1789 with a board lot of 2000 shares.

Goldman Sachs (Asia) L.L.C. is the Sole Sponsor, Sole Global Coordinator and Sole Bookrunner of the global offering. Goldman Sachs (Asia) L.L.C. and Guotai Junan Securities (Hong Kong) Limited are the Joint Lead Managers of the global offering.

AK Medical’s Chairman, Executive Director and Chief Executive Officer, Mr. Li Zhijiang, comments, “The successful listing on the SEHK marks a bright step into the international capital market, and it is also a key milestone towards succeed for AK Medical. The offer shares of AK Medical have been well received under both Hong Kong public tranche and International tranche, which representing well recognition in the capital market. This result revealed the full confidence of the investors in the growth of the company and the orthopedic joint implant market. We are very honored to receive wide support from our investors. Looking forward, AK Medical’s vision is to become a global leading medical device company, which apply the most advanced 3D-printing technology in orthopedic joint and spine replacement implants in China. AK Medical will further develop the 3D Accurate Construction Technology solutions in the orthopedic joint implant market, optimize cost effective, enhance our research, design, development and manufacturing capacities, strive to provide patients with more precise surgical treatment.”

Mr. Li concluded, “The implementation of “Made in China 2025” initiative, which highlights 3D-printing as a priority sector, by the Chinese government further boosts the development of 3D-printing technologies and applications, favoring AK Medical’s advantageous position in the continuing developing and expanding “3D ACT solutions” in high-end and mass markets and propelling the steady business development. Meanwhile, the Company will expand the breadth of its product portfolio into newly-captured orthopedic product market sectors and explore strategic acquisition and alliance opportunities so as to fully capture the opportunities brought by the development potential of the orthopedic market in China, boost the sustainable growth and profitability of AK Medical, and maximize the return to investors.”

About AK Medical Holdings Limited (“AK Medical”)

AK Medical is the first and only medical device company that has commercialized the application of 3D-printing technology in orthopedic joint and spine replacement implants in China, commanding a leading position in the Chinese orthopedic joint implant market. AK Medical markets its products under the brand name of “AK Medical” (「愛康」), which was the bestselling domestic orthopedic joint implant brand by revenue in2016, according to Frost & Sullivan, and also have the most comprehensive product lines in the orthopedic hip and knee joint implant market among domestic brands in China.

AK Medical developed and introduced its personalized 3D Accurate Construction Technology solutions, or “3D ACT solutions”, in July 2014. The Company currently has three types of 3D-printed products, including 3D-printed hip replacement implants, 3D-printed spinal interbody cages and 3D-printed artificial vertebral bodies, being the first and only 3D-printed orthopedic implants approved by China Food and Drug Administration. Meanwhile, according to Frost & Sullivan, AK Medical is the only company that provides one-stop orthopedic surgical solutions in China, integrating all four services relating to surgical solutions involving 3D-printing technologies, namely 3D-imaging and 3D-modeling, formation of 3D-printed models and patient-specific surgical plans, production of 3D-printed surgical instruments, such as surgical guides, and production of 3D-printed orthopedic implants.